Careful selection of treatment methods with the optimal efficacy to safety consideration is instrumental in achieving the best outcomes. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease
Search Results
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Tyler Buckner, Robert Diep, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Nicolas Gallastegui Crestani, Radhika Gangaraju, Cristhiam Rojas-Hernandez, Samuel Z. Goldhaber, Ibrahim Ibrahim, Timothy Kubal, Andrew D. Leavitt, Ming Lim, Janelle Mann, Simon Mantha, Colleen Morton, Alex Nester, Andrew O’Brien, Thomas L. Ortel, Alexander Pine, Allyson Pishko, Mona Ranade, Amirali Salmasi, Jordan Schaefer, Eliot Williams, Geoffrey Wool, Theodore Wun, Sarah Montgomery, Jamie Nguyen, Deborah Freedman-Cass, and Bailee Sliker
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, John Ragsdale III, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, and Anita Engh
/print certificate. Release date: November 10, 2017; Expiration date: November 10, 2018 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for
Melanoma, Version 2.2013
Featured Updates to the NCCN Guidelines
Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho
: Integrate into professional practice the updates to NCCN Guidelines for Melanoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Melanoma NCCN Guidelines Insights : Metastatic Colon Cancer, Version
Localized Colon Cancer, Version 3.2013
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
: Integrate into professional practice the updates to NCCN Guidelines for localized colon cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for localized colon cancer NCCN Guidelines Insights
Metastatic Colon Cancer, Version 3.2013
Featured Updates to the NCCN Guidelines
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
this activity, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Colon Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Colon Cancer
Antiemesis
David S. Ettinger, Debra K. Armstrong, Sally Barbour, Michael J. Berger, Philip J. Bierman, Bob Bradbury, Georgianna Ellis, Steve Kirkegaard, Dwight D. Kloth, Mark G. Kris, Dean Lim, Laura Boehnke Michaud, Lida Nabati, Kim Noonan, Hope S. Rugo, Darby Siler, Steven M. Sorscher, Sundae Stelts, Lisa Stucky-Marshall, Barbara Todaro, and Susan G. Urba
regimens before treatment with highly emetogenic chemotherapy. 5 , 7 , 8 Although vomiting can often be prevented or substantially decreased with prophylactic antiemetic regimens, nausea is much harder to control. 9 , 10 These NCCN Guidelines are intended
Updates to the Management of Cutaneous Melanoma
Presented by: Douglas B. Johnson
-Leader of the Translational Research and Interventional Oncology Research Program; Clinical Director of Melanoma, Vanderbilt-Ingram Cancer Center; and Vice Chair of the NCCN Guidelines Panel for Melanoma: Cutaneous. He presented the current NCCN Clinical
Soft Tissue Sarcoma, Version 2.2012
Featured Updates to the NCCN Guidelines
Margaret von Mehren, Robert S. Benjamin, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Benjamin Paz, John D. Pfeifer, Raphael E. Pollock, R. Lor Randall, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Sridhar Shankar, Brian A. Van Tine, Jeffrey Wayne, Hema Sundar, and Nicole R. McMillian
NCCN Guidelines Insights : Soft Tissue Sarcoma, Version 2.2012 Version 2.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines and this illustration may not be reproduced in any form without the
Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013
Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar, and Dorothy A. Shead
NCCN Guidelines Insights : Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013 Version 2.2013 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines® and this illustration may not
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification
Presented by: Natalie S. Callander
the Myeloma Clinical Program, Carbone Cancer Center, and Vice Chair of the NCCN Guidelines Panel for Multiple Myeloma. At the NCCN 2023 Annual Congress: Hematologic Malignancies, she highlighted the risk assessment strategies and clinical trial data
